Corporate timeline of Eli Lilly and Company, tracing its founding in 1876 through major product breakthroughs, acquisitions, leadership changes, and financial milestones up to the present day.
Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran, founds Eli Lilly and Company in Indianapolis, Indiana, with initial capital of $1,300. The company focuses on manufacturing high-quality medicines. #pharmaceuticals #history
The company is formally incorporated as Eli Lilly and Company, establishing a board of directors and corporate structure. #pharmaceuticals #corporate
Josiah K. Lilly Sr., son of founder Colonel Eli Lilly, assumes presidency of the company, leading its expansion into scientific research and international markets. #leadership #pharmaceuticals
Eli Lilly opens its first dedicated research laboratory in Indianapolis, marking a shift toward systematic pharmaceutical discovery and development. #research #science
Lilly begins large-scale production of Iletin, the first commercially available insulin, in collaboration with the University of Toronto. This breakthrough transforms diabetes treatment. #diabetes #insulin #medicalbreakthrough
The company expands production capacity with a new plant in Indianapolis to meet growing demand for insulin and other pharmaceuticals. #manufacturing #growth
Lilly becomes a major producer of penicillin for the U.S. military, contributing to the war effort and advancing antibiotic manufacturing techniques. #WWII #penicillin #pharmaceuticals
Eli Lilly, grandson of the founder, is named president and CEO, leading the company during a period of post-war expansion and diversification. #leadership #CEO )
Lilly introduces Vancocin, an antibiotic derived from vancomycin, effective against serious Gram-positive bacterial infections. #antibiotics #pharmaceuticals
The company achieves a milestone of $1 billion in total revenue, reflecting its growth in global pharmaceutical markets. #finance #milestone
Lilly launches Keflex, a cephalosporin antibiotic, which becomes a blockbuster drug and a staple in outpatient antibiotic therapy. #antibiotics #blockbuster
Lilly receives FDA approval for Humulin, the first recombinant DNA human insulin, produced using genetically engineered E. coli. This marks a revolutionary step in biotechnology. #biotechnology #insulin #FDA
Lilly launches Prozac, a selective serotonin reuptake inhibitor (SSRI) for depression, which becomes one of the most widely prescribed antidepressants globally. #antidepressant #Prozac #mentalhealth
Lilly introduces Humalog, a rapid-acting insulin analog that offers improved postprandial glucose control for diabetes patients. #diabetes #insulin
Lilly gains FDA approval for Zyprexa, an atypical antipsychotic for schizophrenia and bipolar disorder. It becomes a top-selling drug but later faces legal issues. #antipsychotic #mentalhealth
The company reports over $10 billion in annual sales for the first time, driven by blockbusters like Prozac and Zyprexa. #finance #growth
Lilly launches Alimta, a chemotherapy drug for malignant pleural mesothelioma and non-small cell lung cancer, later expanding indications. #oncology #cancer
Lilly launches Cialis, a phosphodiesterase-5 inhibitor for erectile dysfunction, competing with Viagra and gaining popularity for its long duration. #pharmaceuticals #Cialis
Lilly faces thousands of lawsuits alleging Zyprexa caused diabetes and weight gain. The company eventually agrees to a $1.4 billion settlement with the U.S. Department of Justice in 2009. #legal #pharmaceuticals
Lilly acquires ImClone Systems for $6.5 billion, gaining access to the cancer drug Erbitux (cetuximab) and a pipeline of oncology candidates. #mergers #acquisitions #oncology
Lilly launches Effient, an antiplatelet drug for acute coronary syndrome, in partnership with Daiichi Sankyo. #cardiovascular #pharmaceuticals
Lilly loses patent protection for Zyprexa, leading to generic competition and a significant decline in revenue from the drug. #patents #pharmaceuticals
Lilly launches Trulicity, a GLP-1 receptor agonist for type 2 diabetes, administered once weekly via a prefilled pen. It becomes a top-selling diabetes drug. #diabetes #GLP1
Lilly partners with Boehringer Ingelheim to develop and market Jardiance (empagliflozin), an SGLT2 inhibitor for diabetes, later gaining cardiovascular outcome benefits. #diabetes #partnership
Lilly launches Cyramza, an anti-VEGFR2 antibody for advanced gastric cancer, as part of its oncology portfolio expansion. #oncology #cancer
Lilly obtains FDA approval for Taltz, an IL-17A antagonist for moderate-to-severe plaque psoriasis, later approved for psoriatic arthritis and ankylosing spondylitis. #immunology #psoriasis
Lilly receives FDA approval for Verzenio, a CDK4/6 inhibitor for advanced breast cancer, expanding its oncology franchise. #oncology #breastcancer
David A. Ricks succeeds John Lechleiter as chief executive officer of Eli Lilly, focusing on innovation, digital transformation, and pipeline expansion. #leadership #CEO
Lilly completes the initial public offering of Elanco Animal Health, spinning off its animal health division into an independent publicly traded company. #corporate #spin-off
Lilly acquires Armo BioSciences for $1.6 billion, gaining access to pegilodecakin, an IL-10 pathway agonist for cancer immunotherapy. #acquisitions #immunotherapy
Lilly acquires Loxo Oncology for $8 billion, obtaining a portfolio of precision cancer medicines including Vitrakvi (larotrectinib), a TRK inhibitor. #acquisitions #oncology
In response to the COVID-19 pandemic, Lilly develops bamlanivimab and etesevimab, monoclonal antibody treatments that receive Emergency Use Authorizations. #COVID19 #antibodies
Lilly acquires Dermira for $1.1 billion, gaining access to lebrikizumab, an IL-13 antibody for atopic dermatitis. #acquisitions #dermatology
Lilly acquires Prevail Therapeutics for $1 billion, expanding into gene therapies for neurodegenerative diseases like Parkinson's disease. #gene therapy #neuroscience
Lilly receives FDA approval for Retevmo, a RET inhibitor for non-small cell lung cancer and thyroid cancer, acquired through Loxo Oncology. #oncology #precisionmedicine
Lilly gains FDA approval for Mounjaro, a dual GIP and GLP-1 receptor agonist for type 2 diabetes, showing high efficacy and used off-label for weight loss. #diabetes #weightloss
Lilly reports record $30 billion in annual revenue, driven by strong sales from Trulicity, Verzenio, and newer products. #finance #growth
Lilly announces a $3.7 billion investment to build a new manufacturing site in Indiana, boosting production of active pharmaceutical ingredients and biologics. #manufacturing #investment
Lilly reports positive Phase 3 results for donanemab, an anti-amyloid antibody for Alzheimer's disease, leading to FDA approval filing. #alzheimers #neuroscience
Lilly launches Jaypirca, a non-covalent BTK inhibitor for mantle cell lymphoma, approved for patients who have failed prior therapies. #oncology #lymphoma
